The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research
Open accessPublished version of a preprint
The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index; 38 of the 52 sources its claims cite were checked for support.
Abstract
Reproducible science requires transparent reporting. The ARRIVE guidelines (Animal Research: Reporting of In Vivo Experiments) were originally developed in 2010 to improve the reporting of animal research. They consist of a checklist of information to include in publications describing in vivo experiments to enable others to scrutinise the work adequately, evaluate its methodological rigour, and reproduce the methods and results. Despite considerable levels of endorsement by funders and journals over the years, adherence to the guidelines has been inconsistent, and the anticipated improvements in the quality of reporting in animal research publications have not been achieved. Here, we introduce ARRIVE 2.0. The guidelines have been updated and information reorganised to facilitate their use in practice. We used a Delphi exercise to prioritise and divide the items of the guidelines into 2 sets, the "ARRIVE Essential 10," which constitutes the minimum requirement, and the "Recommended Set," which describes the research context. This division facilitates improved reporting of animal research by supporting a stepwise approach to implementation. This helps journal editors and reviewers verify that the most important items are being reported in manuscripts. We have also developed the accompanying Explanation and Elaboration (E&E) document, which serves (1) to explain the rationale behind each item in the guidelines, (2) to clarify key concepts, and (3) to provide illustrative examples. We aim, through these changes, to help ensure that researchers, reviewers, and journal editors are better equipped to improve the rigour and transparency of the scientific process and thus reproducibility.
Overview
CoChat Summary
TL;DR
ARRIVE 2.0 updates the 2010 ARRIVE reporting guidelines for in vivo animal research, reorganising 21 items into the “ARRIVE Essential 10” minimum set and a “Recommended Set” for research context. The revision used a Delphi exercise and an accompanying Explanation and Elaboration document to improve transparency, methodological scrutiny, and reproducibility.
Key findings
- Despite endorsement by more than a thousand journals, adherence to the original ARRIVE guidelines has been inconsistent: randomisation was reported in only 30%–40% of publications, blinding in approximately 20%, sample size justification in less than 10%, and all basic animal characteristics in less than 10%.
- ARRIVE 2.0 divides items into two prioritised groups with no ranking within each group: the “ARRIVE Essential 10” as the minimum requirement and the “Recommended Set” to describe research context; together they comprise items 1–21.
- New additions include inclusion and exclusion criteria, protocol registration, and data access in line with the FAIR Data Principles; the accompanying Explanation and Elaboration document explains each item’s rationale, clarifies key concepts, and provides illustrative examples.
- A Delphi exercise with experts from 19 countries ranked items by relative importance for assessing reliability of research findings, and the revised guidelines were road tested with researchers preparing manuscripts describing in vivo studies.
Methods
- Guideline revision by an international working group with expertise across life sciences, including funders, journal editors, statisticians, methodologists, and academic/industry researchers.
- A Delphi exercise with external stakeholders from 19 countries provided feedback, suggested new items, and ranked items by importance; demographics and full methods/results are in Supporting Information S1 Delphi and S1 Data.
- Following BioRxiv publication, the revised guidelines and E&E were road tested with researchers preparing in vivo manuscripts; this study is presented in Supporting Information S1 Road Testing and S2 Data.
Limitations
- The paper states two main factors limit the impact of ARRIVE: the extent to which editorial and journal staff actively enforce reporting standards, and insufficient awareness among researchers and organisations of the consequences of incomplete reporting; it cites a PLOS ONE randomised controlled trial where requesting a completed ARRIVE checklist alone failed to improve disclosure.
- The paper also states that the level of resource required from journals and editors likely prohibits implementation of all ARRIVE items.
- The paper does not present a formal limitations section for ARRIVE 2.0 itself; evident from the text, the main article reports no empirical evaluation of ARRIVE 2.0’s effect on reporting quality, and road-testing details are placed in Supporting Information rather than the main text.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
15 Valid · 3 Not valid · 2 Not checked · 20 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“animal characteristics (all basic characteristics reported in less than 10% of publications)”
§ The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research > Why good reporting is important
What the sources say
- Could not verifycites [11] MR Macleod, 2015, Risk of bias in reports of in vivo research: a focus for improvement, PLoS Biol sourceExperimental — accuracy not yet measured
The paper’s Abstract (page unavailable) reports how often publications described randomisation, blinded outcome assessment, sample-size calculations and conflicts of interest. Searches for animal characteristics, including species, strain, sex, age and weight, found no passage giving a figure for publications reporting all basic characteristics. The less-than-10% claim therefore cannot be verified from our copy. (LLM, conf=0.72)
- Partly supportedcites [31] MT Avey, 2016, The Devil Is in the Details: Incomplete Reporting in Preclinical Animal Research., PLoS ONE. sourceExperimental — accuracy not yet measured
The Results report poor reporting of animal-related details among 47 preclinical studies, and the Discussion says basic information such as sex and age was routinely omitted. But the Results’ 9% figure refers to allocating animals to experimental groups and to housing and husbandry—not to the proportion of publications reporting all basic animal characteristics. The claimed less-than-10% figure for all characteristics is therefore not established by our copy. (LLM, conf=0.83)
- Disputedcites [32] V Leung, 2018, ARRIVE has not ARRIVEd: Support for the ARRIVE (Animal Research: Reporting of in vivo Experiments) guidelines does not improve the reporting quality of papers in animal welfare, analgesia or anesthesia., PLoS ONE. sourceExperimental — accuracy not yet measured
Table 3 (Results > Items; page unavailable) reports that all experimental-animal characteristics were fully reported in 15.4% and 29.5% of papers in ARRIVE-supporting journals in 2009 and 2015, respectively, and 10.9% of papers in non-supporting journals in 2015. These figures exceed the claimed threshold of less than 10%. (LLM, conf=0.92)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“randomisation (reported in only 30%–40% of publications)”
§ The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research > Why good reporting is important
What the sources say
- Partly supportedcites [11] MR Macleod, 2015, Risk of bias in reports of in vivo research: a focus for improvement, PLoS Biol sourceExperimental — accuracy not yet measured
The paper reports randomisation in 35.7% of CAMARADES publications from 2009–2010, which falls within the claimed range. But the Abstract also reports lower overall rates in its datasets (20%, 24.8%, and 14.4%), so 30%–40% is not supported as an unqualified rate for publications generally. (LLM, conf=0.88)
- Disputedcites [31] MT Avey, 2016, The Devil Is in the Details: Incomplete Reporting in Preclinical Animal Research., PLoS ONE. sourceExperimental — accuracy not yet measured
The Results report randomization as a composite item in 23% of the 47 studies, not 30%–40%. They separately report that 47% used the term “randomization”; neither measure falls within the claimed range. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Disputedcites [32] V Leung, 2018, ARRIVE has not ARRIVEd: Support for the ARRIVE (Animal Research: Reporting of in vivo Experiments) guidelines does not improve the reporting quality of papers in animal welfare, analgesia or anesthesia., PLoS ONE. sourceExperimental — accuracy not yet measured
The Results (Sub-items; page unavailable) state that randomization (sub-item 6b) was reported in more than 50% of the papers studied, contrary to the claimed 30%–40%. The Discussion’s lower 13%–20% figure concerns reporting the allocation method, not reporting randomization itself. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, despite this level of support, recent studies have shown that important information as set out in the ARRIVE guidelines is still missing from most publications sampled.”
§ The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research > Why good reporting is important
What the sources say
- Supportedcites [11] MR Macleod, 2015, Risk of bias in reports of in vivo research: a focus for improvement, PLoS Biol source
The indexed Abstract reports that 797 of 1,168 sampled publications (68%) did not report any of four important risk-of-bias measures. It also notes that reporting remained low even after journals endorsed the ARRIVE guidelines. No page number is supplied in our copy. (LLM, conf=0.90)
- Supportedcites [31] MT Avey, 2016, The Devil Is in the Details: Incomplete Reporting in Preclinical Animal Research., PLoS ONE. source
The Results (page not provided) report that papers published after ARRIVE was introduced still reported fewer than 50% of the assessed reporting items. The Discussion (page not provided) concludes that reporting was generally incomplete, including for details important to assessing study validity. The finding concerns the paper’s sample of preclinical animal studies. (LLM, conf=0.91)
- Supportedcites [32] V Leung, 2018, ARRIVE has not ARRIVEd: Support for the ARRIVE (Animal Research: Reporting of in vivo Experiments) guidelines does not improve the reporting quality of papers in animal welfare, analgesia or anesthesia., PLoS ONE. source
The Discussion, under “Adherence to reporting guidelines remains low despite journal support,” says reporting standards in the sampled papers were low and that reporting of important study-design indicators—randomization, blinding, sample-size calculation, and data handling—remained low. This supports the claim that important ARRIVE information was missing from most sampled publications. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The ARRIVE guidelines (Animal Research: Reporting of In Vivo Experiments) were originally developed in 2010 to improve the reporting of animal research.”
- Also stated in: § Why good reporting is important · plain
“In an attempt to improve the reporting of animal research, the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines were published in 2010.”
§ The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research > Abstract
What the sources say
- Not checked — no full text of the sourcecites [21] C Kilkenny, 2010, Improving bioscience research reporting: ARRIVE-ing at a solution, Lab Anim source
- Not checked — no full text of the sourcecites [22] C Kilkenny, 2010, Animal research: reporting in vivo experiments: the ARRIVE guidelines, J Gene Med source
- Supportedcites [23] C Kilkenny, 2010, Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research, PLoS Biol source
In “Improving the Reporting of Animal Experiments—The ARRIVE Guidelines,” the authors say they led the initiative to produce ARRIVE guidelines for reporting animal research. “Improved Reporting Will Maximise the Output of Published Research” states that the guidelines were developed to improve the information provided in publications. This 2010 paper presents the guidelines, although it notes that drafting began at a June 2009 meeting. (LLM, conf=0.91)
- Supportedcites [24] C Kilkenny, 2010, Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research., Journal of Pharmacology & Pharmacotherapeutics. source
In “Improving the reporting of animal experiments—the ARRIVE guidelines,” the authors say they developed ARRIVE as guidelines for reporting animal research. The paper describes a draft agreed in 2009, while its References list the ARRIVE guidelines’ publications in 2010; thus 2010 is supported as the year the original guidelines appeared, not the year work on them began. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [25] C Kilkenny, 2010, Animal Research: Reporting In Vivo Experiments: the ARRIVE guidelines, J Physiol source
- Supportedcites [26] C Kilkenny, 2010, Animal Research: Reporting In Vivo Experiments: the ARRIVE guidelines, Exp Physiol source
The Funding section identifies this text as the ARRIVE guidelines and says they are excerpted from a 2010 publication titled “Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research.” The publication details in the ITEM RECOMMENDATION section place this version in Experimental Physiology in 2010 (pp. 842–844). (LLM, conf=0.92)
- Supportedcites [27] JC McGrath, 2010, Guidelines for reporting experiments involving animals: the ARRIVE guidelines, Br J Pharmacol source
The Background describes ARRIVE as a newly generated set of guidelines filling a gap in reporting animal studies. The Abstract calls them a new set of guidelines for reporting research involving animals, and the 2010 references establish the date. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [28] C Kilkenny, 2011, Animal Research: Reporting In Vivo Experiments-the ARRIVE Guidelines, J Cereb Blood Flow Metab source
- Not checked — no full text of the sourcecites [29] C Kilkenny, 2012, Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research, Vet Clin Pathol source
- Partly supportedcites [30] C Kilkenny, 2012, Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research, Osteoarthritis Cartilage sourceExperimental — accuracy not yet measured
The section on improving the reporting of animal experiments says ARRIVE was developed to improve reporting and describes a draft agreed at a working-group meeting in June 2009. The References list ARRIVE guideline publications from 2010, but the paper does not establish that the guidelines were originally developed in 2010 rather than first drafted in 2009. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Why good reporting is important · plain
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“blinding (reported in only approximately 20% of publications)”
§ The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research > Why good reporting is important
What the sources say
- Supportedcites [11] MR Macleod, 2015, Risk of bias in reports of in vivo research: a focus for improvement, PLoS Biol source
The passage reporting results for in vivo research from five leading UK institutions states that 201 of 1,165 publications (17.3%) reported blinding, reasonably described as approximately 20%. The paper also reports different rates in other samples, so this figure applies to that cohort rather than all publications. (LLM, conf=0.90)
- Partly supportedcites [31] MT Avey, 2016, The Devil Is in the Details: Incomplete Reporting in Preclinical Animal Research., PLoS ONE. sourceExperimental — accuracy not yet measured
The Results (page not available) identify blinding as a core reporting item and say that none of the core items were reported more than 40% of the time in the 47 studies assessed. Our copy does not give an approximately 20% figure for blinding, and the sample was limited to preclinical studies of acute lung injury treated with mesenchymal stem cells, not publications generally. (LLM, conf=0.78)
- Partly supportedcites [32] V Leung, 2018, ARRIVE has not ARRIVEd: Support for the ARRIVE (Animal Research: Reporting of in vivo Experiments) guidelines does not improve the reporting quality of papers in animal welfare, analgesia or anesthesia., PLoS ONE. sourceExperimental — accuracy not yet measured
The Results (Sub-items; page unavailable) identify blinding as a poorly reported sub-item, and the Discussion says its reporting remained low. Our copy does not give a blinding-specific figure of approximately 20%, so the numerical part of the claim is not verified. (LLM, conf=0.83)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
11 more claims · 6 with their cited sources checked
Create a free account to see all 40 claims and to verify the 3 references still open.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 9
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although there have been debates on sample size calculation and power analysis [3,4,6], the need for an appropriate sample size calculation has become a major trend in research [1,2,7-11].”
From Sample size determination and power analysis using the G*Power software (2021) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The reporting frameworks that have proven durable in other domains, such as CONSORT for randomized trials,40 MIAME for microarray experiments,41 and ARRIVE for animal research,42 emerged from sustained, community-based development, and turned informal good practice into structured requirements only once the underlying science had matured enough to support them.”
From Designing reproducible large-language-model-assisted scientific analyses (2026) · cites this paper as [42]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Some of the highly adopted checklists include CONSORT (Consolidated Standards of Reporting Trials) [19,20], ARRIVE (Animal Research: Reporting of In Vivo Experiments) [13,14], and PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) [21].”
From Open Science 2.0: Towards a truly collaborative research ecosystem (2023) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“To ensure that the recommendations are as clear and useful as possible to the target audience, this document was road tested alongside the revised guidelines with researchers preparing manuscripts describing in vivo research [13].”
From Reporting animal research: Explanation and elaboration for the ARRIVE guidelines 2.0 (2020) · cites this paper as [13]
In the citing paper
“All experiments were designed and reported according to the Animal Research: Reporting of In Vivo Experiments guidelines (Percie du Sert et al., 2020).”
From Complex bioactive nanofibrous dura mater repairs traumatic brain injury (2026) · cites this paper as Percie du Sert et al., 2020
Citations
Cites
The FAIR Guiding Principles for scientific data management and stewardship
Wilkinson, M. D., Dumontier, M., Aalbersberg, I. J., Appleton, G., Axton, M., Baak, A., Blomberg, N., Boiten, J.-W., da Silva Santos, L. B., Bourne, P. E., et al. (2016) · Scientific Data · doi:10.1038/sdata.2016.18 · Cited by 18,423
Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000412 · Cited by 7,300
Self-citationImproving bioscience research reporting: The ARRIVE guidelines for reporting animal research
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.72351 · Cited by 6,277
Self-citationAnimal research: Reporting in vivo experiments: The ARRIVE guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00872.x · Cited by 3,625
Self-citationRaise standards for preclinical cancer research
Begley, C. G., & Ellis, L. M. (2012) · Nature · doi:10.1038/483531a · Cited by 2,979
Reporting animal research: Explanation and elaboration for the ARRIVE guidelines 2.0
Percie du Sert, N., Ahluwalia, A., Alam, S., Avey, M. T., Baker, M., Browne, W. J., Clark, A., Cuthill, I. C., Dirnagl, U., Emerson, M., et al. (2020) · PLOS Biology · doi:10.1371/journal.pbio.3000411 · Cited by 2,677
Self-citationAnimal Research: Reporting in vivo Experiments—The ARRIVE Guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.220 · Cited by 2,012
Self-citationThe preregistration revolution
Nosek, B. A., Ebersole, C. R., DeHaven, A. C., & Mellor, D. T. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1708274114 · Cited by 1,998
Guidelines for reporting experiments involving animals: the ARRIVE guidelines
McGrath, J., Drummond, G., McLachlan, E., Kilkenny, C., & Wainwright, C. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00873.x · Cited by 1,592
Guidance for Developers of Health Research Reporting Guidelines
Moher, D., Schulz, K. F., Simera, I., & Altman, D. G. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000217 · Cited by 1,437
Cited by
Items 101–200 of 6,206
Chen, L., Lv, X., Guo, Q., Lv, S., Lü, N., Xu, W., Yu, J. M., & Zhang, Y. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15994 · Cited by 70
Wirtz, T. H., Saal, A., Bergmann, I., Fischer, P., Heinrichs, D., Brandt, E. F., Koenen, M. T., Djudjaj, S., Schneider, K. M., Boor, P., et al. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15622 · Cited by 78
Uncovering Disease Mechanisms in a Novel Mouse Model Expressing Humanized APOEε4 and Trem2*R47H
Kotredes, K. P., Oblak, A., Pandey, R. S., Lin, P. B.-C., Garceau, D., Williams, H., Uyar, A., O’Rourke, R., O’Rourke, S., Ingraham, C., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.735524 · Cited by 66
Best, L., Dost, T., Esser, D., Flor, S., Gamarra, A. M., Haase, M., Kadibalban, A. S., Marinos, G., Walker, A., Zimmermann, J., et al. (2025) · Nature Microbiology · doi:10.1038/s41564-025-01959-z · Cited by 65
Wu, X., Kang, L., Tian, J., Wu, Y., Huang, Y., Liu, J., Wang, H., Qiu, G., & Wu, Z. (2022) · Materials Today Bio · doi:10.1016/j.mtbio.2022.100319 · Cited by 72
Bielefeld, P., Martirosyan, A., Martín‐Suárez, S., Apresyan, A., Meerhoff, G. F., Pestana, F., Poovathingal, S. K., Reijner, N., Koning, W., Clement, R. A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49299-6 · Cited by 71
Anfray, A., Schaeffer, S., Hattori, Y., Santisteban, M. M., Casey, N., Wang, G., Strickland, M., Zhou, P., Holtzman, D. M., Anrather, J., et al. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01757-6 · Cited by 53
Fattori, V., Zaninelli, T. H., Rasquel-Oliveira, F. S., Heintz, O. K., Jain, A., Sun, L., Seshan, M. L., Peterse, D., Lindholm, A. E., Anchan, R. M., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adk8230 · Cited by 77
Mohammed, A. K., Alghetaa, H., Zhou, J., Chatterjee, S., Nagarkatti, P. S., & Nagarkatti, M. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15226 · Cited by 69
Chung, E. J., Kwon, S., Reedy, J. L., White, A. O., Song, J. S., Hwang, I., Chung, J., Ylaya, K., Hewitt, S. M., & Citrin, D. E. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.12.035 · Cited by 66
Lambertus, M., Øverberg, L. T., Andersson, K. A., Hjelden, M. S., Hadzic, A., Haugen, Ø. P., Storm‐Mathisen, J., Bergersen, L. H., Geiseler, S., & Morland, C. (2021) · Acta Physiologica · doi:10.1111/apha.13587 · Cited by 61
Mohd, N., Razali, M., Ghazali, M. J., & Kasim, N. H. A. (2022) · Materials · doi:10.3390/ma15072621 · Cited by 64
He, H., He, H., Mo, L., You, Z., & Zhang, J. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.10.031 · Cited by 68
Liu, M., Guo, S., Li, X., Tian, Y., Yu, Y., Tang, L., Sun, Q., Zhang, T., Fan, M., Zhang, L., et al. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s484531 · Cited by 68
Jiang, Q., Liu, C., Liu, S., Lu, W., Li, Y., Luo, X., Ma, R., Zhang, C., Chen, H., Chen, Y., et al. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15285 · Cited by 60
Genome-wide association studies for growth traits in broilers
Dou, D., Shen, L., Zhou, J., Cao, Z., Luan, P., Li, Y., Xiao, F., Guo, H., Li, H., & Zhang, H. (2022) · BMC Genomic Data · doi:10.1186/s12863-021-01017-7 · Cited by 84
Hu, L.-T., Wang, B.-Y., Fan, Y., Hu, L., & Zheng, W. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.346551 · Cited by 61
Delivery of gene therapy through a cerebrospinal fluid conduit to rescue hearing in adult mice
Mathiesen, B. K., Miyakoshi, L. M., Cederroth, C. R., Tserga, E., Versteegh, C. P. C., Bork, P. A. R., Hauglund, N. L., Gomolka, R. S., Mori, Y., Edvall, N. K., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abq3916 · Cited by 63
Zhao, X., Du, Y., Yao, Y., Dai, W., Yin, Y., Wang, G., Li, Y., & Zhang, L. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241249436 · Cited by 71
Franco, N. H., Miranda, S. B., Kovács, N., Nagy, A. C., Thiện, B. Q., Reis, F., & Varga, O. (2021) · Biology · doi:10.3390/biology10020155 · Cited by 60
Ma, C., Wu, H., Yang, G., Xiang, J., Feng, K., Zhang, J., Hua, Y., Kang, L., Fan, G., & Yang, S. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15720 · Cited by 63
Chen, S., Tian, H., Gong, Q., Cai, L., Yao, J., Wang, W., & Yang, D. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.335163 · Cited by 66
Successful 3-day lung preservation using a cyclic normothermic ex vivo lung perfusion strategy
Ali, A., Nykänen, A. I., Beroncal, E. L., Brambate, E., Mariscal, A., Michaelsen, V. S., Wang, A., Kawashima, M., Ribeiro, R. V. P., Zhang, Y., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104210 · Cited by 64
Reporting guidelines used varying methodology to develop recommendations
Schlussel, M. M., Sharp, M. K., de Beyer, J. A., Kirtley, S., Logullo, P., Dhiman, P., MacCarthy, A., Koroleva, A., Speich, B., Bullock, G. S., et al. (2023) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2023.03.018 · Cited by 59
Alonso‐Miguel, D., Valdivia, G., Guerrera, D., Alenza, M. D. P., Pantelyushin, S., Alonso‐Diez, Á., Beiss, V., Fiering, S., Steinmetz, N. F., Suárez-Redondo, M., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004044 · Cited by 58
A comprehensive tool box for large animal studies of intervertebral disc degeneration
Lee, N. N., Salzer, E., Bach, F. C., Bonilla, A. F., Cook, J. L., Gazit, Z., Grad, S., Ito, K., Smith, L. J., Vernengo, J., et al. (2021) · JOR Spine · doi:10.1002/jsp2.1162 · Cited by 64
Sex-Specific Immune Responses in Stroke
Banerjee, A., & McCullough, L. D. (2022) · Stroke · doi:10.1161/strokeaha.122.036945 · Cited by 60
Abid, S., Farid, A., Abid, R., Rehman, M. U., Alsanie, W. F., Alhomrani, M., Alamri, A. S., Asdaq, S. M. B., Hefft, D. I., Saqib, S., et al. (2022) · Microorganisms · doi:10.3390/microorganisms10050954 · Cited by 68
Yang, J., Hsu, C., Cao, T., Ye, H., Chen, J., & Li, Y.-Q. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.350212 · Cited by 59
A plant‐derived TRPV3 inhibitor suppresses pain and itch
Han, Y., Luo, A., Kamau, P. M., Takomthong, P., Hu, J., Boonyarat, C., Luo, L., & Lai, R. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15390 · Cited by 56
Huang, J., Li, R., Yang, J., Cai, M., Lee, Y., Wang, A., Cheng, B., & Wang, Y. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.02.023 · Cited by 61
Zhang, G., Lü, J., Zheng, J., Mei, S., Li, H., Zhang, X., Ping, A., Gao, S., Fang, Y., & Yu, J. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.375343 · Cited by 66
Good publication practice in physiology 2021
Jensen, B. L., & Persson, P. B. (2021) · Acta Physiologica · doi:10.1111/apha.13741 · Cited by 56
Evaluation of CRISPR gene-editing tools in zebrafish
Uribe‐Salazar, J. M., Kaya, G., Sekar, A., Weyenberg, K., Ingamells, C., & Dennis, M. Y. (2022) · BMC Genomics · doi:10.1186/s12864-021-08238-1 · Cited by 62
Lucas, R. J., Allen, A. E., Brainard, G. C., Brown, T. M., Dauchy, R. T., Didikoğlu, A., Do, M. T. H., Gaskill, B. N., Hattar, S. S., Hawkins, P., et al. (2024) · PLoS Biology · doi:10.1371/journal.pbio.3002535 · Cited by 62
Ha, N., Choi, Y. I., Jung, N., Song, J. Y., Bae, D. K., Kim, M. C., Lee, Y. J., Song, H., Kwak, G., Jeong, S., et al. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15231 · Cited by 55
tPA Deficiency Underlies Neurovascular Coupling Dysfunction by Amyloid-β
Park, L., Zhou, J., Koizumi, K., Wang, G., Anfray, A., Ahn, S. J., Seo, J., Zhou, P., Zhao, L., Paul, S. M., et al. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.1140-20.2020 · Cited by 60
Shen, J., Guo, H., Liu, S., Jin, W., Zhang, Z., Zhang, Y., Liu, K., Mao, S., Zhou, Z., Xie, L. Y., et al. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15965 · Cited by 55
Alterations in gut microbiota are related to metabolite profiles in spinal cord injury
Jiang, J.-H., Ning, B., Kang, J.-N., Sun, Z.-F., Li, X., Zhang, X., Jin, Z., Zhang, C., Zhang, Y., Wang, H., et al. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.355769 · Cited by 55
Improving preclinical studies through replications
Drude, N., Martinez‐Gamboa, L., Danziger, M., Dirnagl, U., & Toelch, U. (2021) · eLife · doi:10.7554/elife.62101 · Cited by 63
Self-citationThe design of animal experiments
Bate, S. T., & Stanford, S. C. (2024) · Wiley eBooks · doi:10.1002/9781119555278.ch3 · Cited by 55
Long non-coding RNA ACTA2-AS1 promotes ductular reaction by interacting with the p300/ELK1 complex
Navarro‐Corcuera, A., Sehrawat, T. S., Jalan‐Sakrikar, N., Gibbons, H. R., Pirius, N., Khanal, S., Hamdan, F. H., Aseem, S. O., Cao, S., Bañales, J. M., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.014 · Cited by 59
Wang, S.-Y., Fu, X., Duan, R., Wei, B., Cao, H., Yan, E., Chen, S., Zhang, Y.-D., & Jiang, T. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.346468 · Cited by 57
Rao, Q., Ma, G., Li, M., Wu, H., Zhang, Y., Zhang, C.-E., Ma, Z., & Huang, L. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15958 · Cited by 54
Aggression in Group-Housed Male Mice: A Systematic Review
Weber, E. M., Zidar, J., Ewaldsson, B., Askevik, K., Udén, E., Svensk, E., & Törnqvist, E. (2022) · Animals · doi:10.3390/ani13010143 · Cited by 72
Zhu, D., Huang, Y., Guo, S., Li, N., Yang, X., Sui, A., Wu, Q., Zhang, Y., Kong, Y., Li, Q., et al. (2023) · Advanced Science · doi:10.1002/advs.202205862 · Cited by 69
Karpale, M., Käräjämäki, A. J., Kummu, O., Gylling, H., Hyötyläinen, T., Orešič, M., Tolonen, A., Hautajärvi, H., Savolainen, M. J., Ala‐Korpela, M., et al. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15433 · Cited by 56
The T‐type calcium channel antagonist, Z944, reduces spinal excitability and pain hypersensitivity
Harding, E. K., Dedek, A., Bonin, R. P., Salter, M. W., Snutch, T. P., & Hildebrand, M. E. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15498 · Cited by 56
Lou, J., Zhang, H., Qi, J., Xu, Y. M., Wang, X., Jiang, J., Hu, X., Ni, L., Cai, Y., Wang, X., et al. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15702 · Cited by 54
Suppression of myeloid PFKFB3‐driven glycolysis protects mice from choroidal neovascularization
Liu, Z., Mao, X., Yang, Q., Zhang, X., Xu, J., Ma, Q., Zhou, Y., Da, Q., Cai, Y., Sopeyin, A., et al. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15925 · Cited by 61
Li, G., Liu, C., Yang, L., Feng, L., Zhang, S., Li, J., Cheng, T., Li, J., Gao, Y., Pan, Z., et al. (2023) · Cell Biology and Toxicology · doi:10.1007/s10565-023-09790-0 · Cited by 60
Synthesis and pharmacological activity of the epimers of hexahydrocannabinol (HHC)
Russo, F., Vandelli, M. A., Biagini, G., Schmid, M. G., Luongo, L., Perrone, M., Ricciardi, F., Maione, S., Laganà, A., Capriotti, A. L., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-38188-5 · Cited by 52
Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer
Hoppe, M. M., Jaynes, P. W., Wardyn, J. D., Srinivas, U. S., Tan, T. Z., Lie, S., Lim, D. G., Pang, B., Lim, S., Yeong, J. P.-S., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013366 · Cited by 57
Whittaker, A. L., Liu, Y., & Barker, T. H. (2021) · Animals · doi:10.3390/ani11030673 · Cited by 63
Kao, T., Chen, P., Wang, Y., Tseng, H., Chang, S., Wu, T., Yang, S., Lee, Y., & Hwang, T. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15597 · Cited by 53
Hu, Z., Yu, P., Zhang, Y., Yang, Y., Zhu, M., Qin, S., Xu, J., Duan, D.-X., Wu, Y., Wang, D., et al. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01862-9 · Cited by 56
Sparks, D. S., Savi, F. M., Dlaska, C. E., Saifzadeh, S., Brierly, G. I., Ren, E., Cipitria, A., Reichert, J. C., Wille, M., Schuetz, M., et al. (2023) · Science Advances · doi:10.1126/sciadv.add6071 · Cited by 57
A brief guide to the science and art of writing manuscripts in biomedicine
Forero, D. A., López‐León, S., & Perry, G. L. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02596-2 · Cited by 57
Das, S., Goossens, J., Jacobs, D., Dewit, N., Pijnenburg, Y. A. L., In ‘t Veld, S. G. J. G., Teunissen, C. E., & Vanmechelen, E. (2023) · Alzheimer's Research & Therapy · doi:10.1186/s13195-023-01212-x · Cited by 50
Li, F., Jiang, M., Ma, M., Chen, X., Zhang, Y., Zhang, Y., Yu, Y., Cui, Y., Chen, J., Zhao, H., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.09.009 · Cited by 50
AXL inhibition improves BRAF-targeted treatment in melanoma
Nyakas, M., Fleten, K. G., Haugen, M. H., Engedal, N., Sveen, C., Farstad, I. N., Flørenes, V. A., Prasmickaite, L., Mælandsmo, G. M., & Seip, K. (2022) · Scientific Reports · doi:10.1038/s41598-022-09078-z · Cited by 54
Smith, K. L. M., Swiderska, A., Lock, M. C., Graham, L., Iswari, W., Choudhary, T., Thomas, D., Kowash, H. M., Desforges, M., Cottrell, E. C., et al. (2022) · Journal of Pineal Research · doi:10.1111/jpi.12821 · Cited by 59
Liu, T., Wang, P., Yin, H., Wang, X., Lv, J., Jiang, Y., Zhu, J. F., & Wang, Y. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.371381 · Cited by 52
Jiang, J., Pan, H., Shen, F., Tan, Y., & Chen, S. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.373715 · Cited by 53
Dalla, C., Jarić, I., Pavlidi, P., Hodes, G. E., Kokras, N., Bespalov, A., Kas, M. J., Steckler, T., Kabbaj, M., Würbel, H., et al. (2023) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2023.110003 · Cited by 59
Self-citationKolgazi, M., Çilingir, S., Yilmaz, O., Gemici, M., Yazar, H., Özer, S., Elmas, M. A., Arbak, S., & Süyen, G. G. (2020) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2020.109351 · Cited by 49
Chen, D., Chen, L., Guo, Y. P., Wu, X., Zhao, T., Zhao, H., Zhang, H., Yan, M., Zhang, G., & Li, P. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-01026-x · Cited by 55
Zhang, Z., Wu, W., Jiao, H., Chen, Y., Ji, X., Cao, J., Yin, F., & Yin, W. (2022) · British Journal of Pharmacology · doi:10.1111/bph.16024 · Cited by 50
Strauß, F. J., Park, J., Lee, J., Schiavon, L., Smirani, R., Hitz, S., Chantler, J. G. M., Mattheos, N., Jung, R. E., Bosshardt, D. D., et al. (2024) · Journal Of Clinical Periodontology · doi:10.1111/jcpe.14070 · Cited by 49
Wan, H., Ban, X.-X., He, Y., Yang, Y., Hu, X., Shang, L., Wan, X.-X., Zhāng, Q., & Xiong, K. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00674 · Cited by 54
Thomson, K., Kelly, T., Karouta, C., Morgan, I. G., & Ashby, R. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15629 · Cited by 51
SAFit2 reduces neuroinflammation and ameliorates nerve injury-induced neuropathic pain
Wedel, S., Mathoor, P., Rauh, O., Heymann, T., Ciotu, C. I., Fuhrmann, D. C., Fischer, M. J. M., Weigert, A., de Bruin, N. M. W. J., Hausch, F., et al. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02615-7 · Cited by 49
A Call to Action for New Global Approaches to Cardiovascular Disease Drug Solutions
Figtree, G. A., Broadfoot, K., Casadei, B., Califf, R. M., Crea, F., Drummond, G. R., Freedman, J. E., Guzik, T. J., Harrison, D. G., Hausenloy, D. J., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000981 · Cited by 49
Time‐dependent dual effect of NLRP3 inflammasome in brain ischaemia
Palomino‐Antolín, A., Narros‐Fernández, P., Farré‐Alins, V., Sevilla‐Montero, J., Decouty‐Pérez, C., López-Rodríguez, A. B., Fernández, N., Monge, L., Casas, A. I., Calzada, M. J., et al. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15732 · Cited by 50
da Silva, A. A. F., Rinco, U. G. R., Jacob, R. G. M., Sakai, V. T., & Mariano, R. C. (2021) · Clinical Oral Investigations · doi:10.1007/s00784-021-04038-9 · Cited by 47
Vollert, J., Macleod, M. R., Dirnagl, U., Kas, M. J., Michel, M. C., Potschka, H., Riedel, G., Wever, K. E., Würbel, H., Steckler, T., et al. (2022) · Nature Methods · doi:10.1038/s41592-022-01615-y · Cited by 51
Self-citationDesigning, conducting, and reporting reproducible animal experiments
Wilson, E., Ramage, F. J., Wever, K. E., Sena, E. S., Macleod, M. R., & Currie, G. L. (2023) · Journal of Endocrinology · doi:10.1530/joe-22-0330 · Cited by 44
Self-citationTang, X., Yan, T., Wang, S., Liu, Q., Yang, Q., Zhang, Y., Li, Y., Wu, Y., Liu, S., Ma, Y., et al. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.380904 · Cited by 48
Yahata, T., Ibrahim, A. A., Fujimura, T., Uno, T., Terada, T., Hirano, K.-I., Hosokawa, H., Ohta, A., Miyata, T., & Ando, K. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1365894 · Cited by 48
Lin, L., Sun, B., Hu, Y., Yang, W., Li, J., Wang, D., Zhang, L., Lu, M., Li, Y., Li, Y., et al. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70032 · Cited by 51
Wang, L., Zhang, X., Cao, Y., Ma, Q., Mao, X., Xu, J., Yang, Q., Zhou, Y., Lucas, R., Fulton, D. J., et al. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15339 · Cited by 48
Singleton, S., Baptista‐Hon, D. T., Edelsten, E., McCaughey, K. S., Camplisson, E., & Hales, T. G. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15409 · Cited by 49
Nam, M., Park, J., Song, H. J., Choi, J., Kim, S., Jang, B. K., Yoon, H. H., Heo, J. Y., Lee, H., An, H., et al. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01097-4 · Cited by 49
What’s wrong with my experiment?: The impact of hidden variables on neuropsychopharmacology research
Butler-Struben, H. M., Kentner, A. C., & Trainor, B. C. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01309-1 · Cited by 56
Metabolomics in endometriosis: challenges and perspectives for future studies
Ortiz, C. N., Torres-Reverón, A., & Appleyard, C. B. (2021) · Reproduction and Fertility · doi:10.1530/raf-20-0047 · Cited by 56
Zaninelli, T. H., Fattori, V., Saraiva‐Santos, T., Badaro‐Garcia, S., Staurengo‐Ferrari, L., Andrade, K. C., Artero, N. A., Ferraz, C. R., Bertozzi, M. M., Rasquel-Oliveira, F. S., et al. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15897 · Cited by 47
Jiang, F.-Q., Liu, K., Chen, J., Cao, Y., Chen, W.-Y., Zhao, W.-L., Song, G., Liang, C.-Q., Zhou, Y.-M., Huang, H., et al. (2022) · eLife · doi:10.7554/elife.77014 · Cited by 47
Huang, Q., Yao, Y., Wang, Y., Li, J., Chen, J., Wu, M., Chen, G., Lou, J., Yang, W., Zhao, L., et al. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2023.12.012 · Cited by 51
Giavaresi, G., Bellavia, D., Luca, A. D., Costa, V., Raimondi, L., Cordaro, A., Sartori, M., Terrando, S., Toscano, A., PIGNATTI, G., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010282 · Cited by 46
A call to action for new global approaches to cardiovascular disease drug solutions
Figtree, G. A., Broadfoot, K., Casadei, B., Califf, R. M., Crea, F., Drummond, G. R., Freedman, J. E., Guzik, T. J., Harrison, D. G., Hausenloy, D. J., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab068 · Cited by 50
Senk, A., & Djonov, V. (2021) · Scientific Reports · doi:10.1038/s41598-021-98852-6 · Cited by 45
Holyoak, G. R., Premathilake, H., Lyman, C., Sones, J. L., Gunn, A. J., Wieneke, X., & DeSilva, U. (2022) · Scientific Reports · doi:10.1038/s41598-022-18971-6 · Cited by 56
CDR1as regulates α-synuclein-mediated ischemic brain damage by controlling miR-7 availability
Mehta, S. L., Chokkalla, A. K., Bathula, S., Arruri, V. K., Chelluboina, B., & Vemuganti, R. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.11.022 · Cited by 46
A Systematic Review of Animal Models of Disuse-Induced Bone Loss
Brent, M. B., Brüel, A., & Thomsen, J. S. (2021) · Calcified Tissue International · doi:10.1007/s00223-020-00799-9 · Cited by 50
Han, N., Zhang, W., Fang, X., Li, Q.-C., & Pi, W. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.343889 · Cited by 48
Borsom, E. M., Conn, K. A., Keefe, C. R., Herman, C., Orsini, G. M., Hirsch, A. H., Avila, M. P., Testo, G., Jaramillo, S. A., Bolyen, E. K., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.03458-22 · Cited by 47
Tradition, not science, is the basis of animal model selection in translational and applied research
Veening-Griffioen, D. H., Ferreira, G. S., Boon, W. P. C., Wied, C. C. G.-D., Schellekens, H., Moors, E. H. M., & Meer, P. J. K. V. (2020) · ALTEX · doi:10.14573/altex.2003301 · Cited by 44
Yang, M., Chen, Q., Li, M., Wen, G., An, W., Zhou, X., Niu, K., Liu, C., Ren, M., Sun, K., et al. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15583 · Cited by 44
Samojeden, C. G., Pavan, F. A., Rutkoski, C. F., Folador, A., da Fré, S. P., Müller, C., Hartmann, P. A., & Hartmann, M. T. (2022) · Scientific Reports · doi:10.1038/s41598-022-16039-z · Cited by 47
Platelet-rich plasma promotes peripheral nerve regeneration after sciatic nerve injury
Wang, Y., Liu, X., Kang, Z.-C., & Kang, Z. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.346461 · Cited by 44
Metadata
- Authors
- Percie du Sert, N., Hurst, V., Ahluwalia, A., Alam, S., Avey, M. T., Baker, M., Browne, W. J., Clark, A., Cuthill, I. C., Dirnagl, U., Emerson, M., Garner, P., Holgate, S. T., Howells, D. W., Karp, N. A., Lazic, S. E., Lidster, K., MacCallum, C. J., Macleod, M., Pearl, E. J., Petersen, O. H., Rawle, F., Reynolds, P., Rooney, K., Sena, E. S., Silberberg, S. D., Steckler, T., & Würbel, H.
- Affiliations
- National Centre for the Replacement Refinement and Reduction of Animals in Research (GB)
- Queen Mary University of London (GB)
- Taylor and Francis (United Kingdom)
- University of Bristol (GB)
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- Imperial College London (GB)
- Liverpool School of Tropical Medicine (GB)
- University of Southampton (GB)
- University of Tasmania (AU)
- AstraZeneca (United Kingdom) (GB)
- Prioris.ai (Canada) (CA)
- Hindawi (United Kingdom) (GB)
- University of Edinburgh (GB)
- Cardiff University (GB)
- Medical Research Council (GB)
- University of Florida (US)
- The University of Sydney (AU)
- National Institute of Neurological Disorders and Stroke (US)
- Janssen (Belgium) (BE)
- University of Bern (CH)
- ORCID
- Percie du Sert, Nathalie
- Hurst, Viki
- Ahluwalia, Amrita
- Alam, Sabina
- Avey, Marc T.
- Browne, William J.
- Clark, Alejandra
- Cuthill, Innes C.
- Dirnagl, Ulrich
- Emerson, Michael
- Garner, Paul
- Holgate, Stephen T.
- Howells, David W.
- Karp, Natasha A.
- Lazic, Stanley E.
- MacCallum, Catriona J.
- Macleod, Malcolm
- Pearl, Esther J.
- Petersen, Ole H.
- Rawle, Frances
- Reynolds, Penny
- Rooney, Kieron
- Sena, Emily S.
- Silberberg, Shai D.
- Steckler, Thomas
- Würbel, Hanno
- Venue
- PLOS Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2020-07-14
- Volume
- 18
- Issue
- 7
- Pages
- e3000410
- ISSN
- 1544-9173 (ISSN-L)
- 1545-7885
- PMC
- PMC7360023
- OpenAlex
- W4236357753
- Cited by
- 5,939
- References
- 60
- Citations by year
- 2026: 1201 · 2025: 1307 · 2024: 994 · 2023: 920 · 2022: 823 · 2021: 579 · 2020: 106
- FWCI
- 520.24
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- public-domain
- creativecommons.org/publicdomain/zero/1.0/ (vor)
- Locations
- PLoS Biology (publishedVersion, public-domain)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, public-domain)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by)
- Bristol Research (University of Bristol) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion, other-oa)
- Funders
- National Centre for the Replacement, Refinement and Reduction of Animals in Research
- Topics
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
- Social Sciences › Library and Information Sciences › Academic Writing and Publishing
- Keywords
- ARRIVE guidelines, animal research reporting, in vivo experiments, research transparency, reproducibility, reporting checklist, methodological quality, peer review, journal editorial policy
- MeSH terms
- Animals, Guidelines as Topic, Animal Experimentation, Checklist, Research Report
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-24, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-24 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.